Synergy pharmaceuticals, inc. (SGYP)
Balance Sheet / Yearly
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Dec'10
ASSETS
Current Assets:
Cash and cash equivalents

45,647

61,233

98,658

136,986

117,787

81,960

139,262

82,387

109,090

141,219

84,155

61,653

41,916

61,695

78,718

146,470

12,769

1,200

20,635

18,130

12,064

8,312

9,067

12,416

17,244

27,426

6,123

13,245

67

503

1,707

Accounts receivable

9,222

8,511

7,414

6,491

5,036

1,782

6,319

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Available-for-sale securities

-

-

-

-

-

-

-

-

0

0

0

50,097

100,085

99,984

99,910

49,897

19,999

49,999

50,003

50,027

70,041

83,988

12,049

20,086

20,123

16,149

-

-

-

-

-

Inventories

21,530

17,609

16,175

17,214

13,045

11,853

9,647

5,640

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

5,259

7,772

8,924

4,469

8,560

8,368

8,038

889

1,744

4,266

3,361

3,305

1,147

2,287

3,649

3,836

4,106

4,798

5,578

3,718

5,244

2,349

1,573

1,547

1,285

1,408

1,617

1,063

588

861

997

Total Current Assets

81,658

95,125

131,171

165,160

144,428

103,963

163,266

88,916

110,834

145,485

87,516

115,055

143,148

163,966

182,277

200,203

36,874

55,997

76,216

71,875

87,349

94,649

22,689

34,049

38,652

44,985

7,740

14,308

655

1,365

2,705

Property and equipment, net

1,069

1,168

1,163

1,134

1,045

529

568

593

635

724

534

531

590

584

617

642

607

589

589

589

617

489

108

30

1

2

5

6

6

6

7

Available-for-sale securities long term

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,010

-

-

-

-

-

Security deposits

312

312

312

312

318

407

408

343

343

343

343

343

219

219

219

163

163

163

94

94

94

94

93

20

19

19

14

14

14

14

14

Deferred financing costs, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,719

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Due from controlling shareholder

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,306

-

-

-

-

-

-

-

Due from Callisto Pharmaceuticals, Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,655

1,936

1,819

1,542

1,427

1,378

1,674

Total Assets

83,039

96,605

132,646

166,606

145,791

104,899

164,242

89,852

111,812

146,552

88,393

115,929

143,957

164,769

194,832

201,008

37,644

56,749

76,899

72,558

88,060

95,232

22,890

37,405

41,329

50,954

9,579

15,870

2,103

2,764

4,400

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Accounts payable

11,549

12,912

22,976

23,256

17,182

30,460

28,445

15,584

15,801

19,028

13,561

13,263

11,612

10,606

11,170

13,869

15,246

12,223

9,931

13,542

10,275

4,980

5,978

5,255

2,505

1,154

2,084

1,416

4,469

2,627

2,961

Accrued expenses

21,225

15,453

13,933

14,658

14,208

12,390

10,203

13,552

5,242

3,109

3,229

4,328

3,177

3,934

1,710

1,962

3,355

5,713

2,663

2,134

2,892

2,989

3,312

2,060

2,469

3,765

965

1,331

2,330

2,193

2,051

Interest payable on senior convertible notes

581

233

581

233

581

233

581

294

2,474

990

2,474

1,988

4,969

2,222

6,250

2,500

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

5,000

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Senior convertible notes, net

17,834

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Term Loan, net

101,739

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenues

-

5,000

5,000

-

1,927

1,498

4,260

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total Current Liabilities

157,928

33,598

42,490

38,147

33,898

44,581

43,489

29,430

23,517

23,127

19,264

19,579

19,758

16,762

19,130

18,331

18,601

17,936

12,594

15,676

13,167

7,969

9,290

7,315

4,975

4,919

3,049

2,747

6,800

4,820

5,012

Senior convertible notes, net

0

17,657

17,480

17,302

17,125

16,948

16,771

22,665

76,070

75,818

75,565

151,241

150,735

167,967

200,000

187,664

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Term Loan, net

0

-

-

98,660

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Long term debt, net

-

100,327

98,965

-

95,977

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Derivative financial instruments, at estimated fair value-warrants

9,767

9,334

11,938

17,582

0

55

94

216

171

85

62

322

533

1,981

440

172

130

555

1,311

1,534

1,050

973

6,351

5,258

4,663

4,803

3,317

3,325

3,860

7,958

3,487

Deferred revenue, net of current portion

11,236

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

352

379

406

433

460

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total Liabilities

179,283

161,295

171,279

172,124

147,460

61,584

60,354

52,311

99,758

99,030

94,891

171,142

171,026

186,710

219,570

206,167

18,731

18,491

13,905

17,210

14,217

8,942

15,641

12,573

9,638

9,723

6,366

6,072

10,661

12,779

8,500

Commitments and contingencies

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Stockholders Deficit
Preferred stock, authorized 20,000,000 shares and none outstanding, at September 30, 2018 and December 31, 2017

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

-

-

0

Common stock, par value of $.0001, 400,000,000 shares authorized at June 30, 2018 and December 31, 2017. Issued and outstanding 248,037,301 shares and 246,660,367 shares at September 30, 2018 and December 31, 2017, respectively.

25

25

25

25

23

23

23

20

18

18

15

11

11

12

10

11

10

10

10

10

10

10

8

7

6

6

5

6

9

9

4

Additional paid-in capital

811,399

808,410

804,776

801,787

768,664

764,777

751,461

620,513

535,161

530,386

437,813

329,161

326,858

305,989

269,526

261,715

255,233

251,570

250,386

226,515

225,159

224,069

134,991

133,878

128,759

128,415

79,839

79,401

55,415

53,376

51,037

Accumulated deficit

-907,668

-873,125

-843,434

-807,330

-770,356

-721,485

-647,596

-582,992

-523,125

-482,882

-444,326

-384,385

-353,938

-327,942

-294,274

-266,885

-236,330

-213,322

-187,402

-171,177

-151,326

-137,789

-127,750

-109,053

-97,075

-87,190

-76,631

-69,609

-63,983

-63,400

-55,141

Total Stockholders Deficit

-96,244

-64,690

-38,633

-5,518

-1,669

43,315

103,888

37,541

12,054

47,522

-6,498

-55,213

-27,069

-21,941

-24,738

-5,159

18,913

38,258

62,994

55,348

73,843

86,290

7,249

24,832

31,691

41,231

3,212

9,798

-8,558

-

-4,099

Total Stockholders' Deficit

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,014

-

Total Liabilities and Stockholders Deficit

83,039

96,605

132,646

166,606

145,791

104,899

164,242

89,852

111,812

146,552

88,393

115,929

143,957

164,769

194,832

201,008

37,644

56,749

76,899

72,558

88,060

95,232

22,890

37,405

41,329

50,954

9,579

15,870

2,103

2,764

4,400